Cell Signaling Technology

Product Pathways - Wnt / Hedgehog / Notch

TCF1 (C63D9) Rabbit mAb #2203

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP IHC-P IF-IC F H M Endogenous 48, 50 kDa Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IHC-P=Immunohistochemistry (Paraffin)  IF-IC=Immunofluorescence (Immunocytochemistry)  F=Flow Cytometry
Reactivity Key:  H=Human  M=Mouse
Species cross-reactivity is determined by Western blot.

Protocols

Specificity / Sensitivity

TCF1 (C63D9) Rabbit mAb detects endogenous levels of total TCF1 protein. This antibody does not recognize the dominant negative isoforms of TCF1 lacking the amino-terminal β-catenin binding domain and does not cross-react with LEF1.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to a region surrounding Pro95 of human TCF1 protein.

Western Blotting

Western Blotting

Western blot analysis of total cell lysates from HCT29, Colo201, Jurkat and mouse thymocytes using TCF1 (C63D9) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human Non-Hodgkin's lymphoma using TCF1 (C63D9) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lung carcinoma using TCF1 (C63D9) Rabbit mAb in the presence of control peptide (left) or TCF1 blocking peptide #1007 (right).


IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human tonsil using TCF1 (C63D9) Rabbit mAb.

Flow Cytometry

Flow Cytometry

Flow cytometric analysis of Jurkat cells using TCF1 (C63D9) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red).

IF-IC

IF-IC

Confocal immunofluorescent analysis of DLD-1 cells using TCF1 (C63D9) Rabbit mAb (green). Actin filaments have been labeled with Alexa Fluor® 555 phalloidin (red).


Background

LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors which consists of the following: Lymphoid enhancer factor 1 (LEF1), T Cell Factor 1 (TCF1), TCF3 and TCF4 (1). LEF1 and TCF1 were originally identified as important factors regulating early lymphoid development (2) that act downstream in Wnt signaling. LEF1 and TCF bind to Wnt response elements to provide docking sites for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1 and TCF proteins are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).

TCF1, also known asTranscription Factor 7 (TCF7), has several isoforms due to alternative splicing and transcription from an alternative promoter. The isoforms generated by the alternative promoter do not contain the amino-terminal β-catenin binding domain and therefore may function in a dominant negative manner (6). TCF1 displays dynamic expression both in the total amount and the type of isoforms expressed in T cells during development and differentiation (7).

  1. Waterman, M.L. (2004) Cancer Metastasis Rev. 23, 41-52.
  2. Schilham, M.W. and Clevers, H. (1998) Semin. Immunol. 10, 127-132.
  3. Brantjes, H. et al. (2002) Biol. Chem. 383, 255-261.
  4. Reya, T. and Clevers, H. (2005) Nature 434, 843-850.
  5. Logan, C.Y. and Nusse, R. (2004) Annu. Rev. Cell Dev. Biol. 20, 781-810.
  6. Waterman, M.L. Cancer Metastasis Rev. 23, 41-52.
  7. Willinger, T. et al. (2006) J. Immunol. 176, 1439-1446.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products